English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/145647
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa

AuthorsMarchena, Miguel; Villarejo-Zori, Beatriz ; Zaldívar-Díez, Josefa; Palomo, Valle ; Gil, Carmen ; Hernández-Sánchez, Catalina ; Martínez, Ana ; De la Rosa, Enrique J.
KeywordsGSK-3 inhibitors
Retinal diseases
Retinitis pigmentosa
Issue Date23-Jan-2017
PublisherTaylor & Francis
CitationJournal of Enzyme Inhibition and Medicinal Chemistry 32 (1) 522-526 (2017)
AbstractRetinitis pigmentosa (RP) is an inherited retinal dystrophy that courses with progressive degeneration of retinal tissue and loss of vision. Currently, RP is an unpreventable, incurable condition. We propose glycogen synthase kinase 3 (GSK-3) inhibitors as potential leads for retinal cell neuroprotection, since the retina is also a part of the central nervous system and GSK-3 inhibitors are potent neuroprotectant agents. Using a chemical genetic approach, diverse small molecules with different potency and binding mode to GSK-3 have been used to validate and confirm GSK-3 as a pharmacological target for RP. Moreover, this medicinal chemistry approach has provided new leads for the future disease-modifying treatment of RP.
Description6 p.-5 fig.
Publisher version (URL)http://dx.doi.org/10.1080/14756366.2016.1265522
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
J.Enz. Inhibit. Med. Chem. 2017.pdfArtículo principal1,13 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.